Search PubMed⌕ Search

Biomedical subjects

M Ollagnier

Publications and source records attributed to M Ollagnier.

89 records · Page 5Linked to original sources
PubMedDate not supplied

[Effects of hypocalcemia on atrioventricular conduction compared with those of agents which inhibit the slow channel (author's transl)].

1. The effects of experimental hypocalcemia were studied on 13 anesthetized and atropinized dogs, measuring endocavitary His bundle recordings, global effective refractory period (ERP) (determination by the extrastimulus method), and sinus rate. These data, including arterial pressure, were observed during a 40 min. I.V. infusion of Na EDTA, 3 mg . kg-1 . min-1. We observed: 1.1. A decrease in serum ionized calcium, from 45,7 mg . 1-1 (control) to 28,1 mg . 1-1 1.2. A moderate, though highly significant, decrease in the intraatrial conduction time (SA interval of His bundle recordings). 1.3. A significant increase in the AV node conduction time (AH). 1.4. No significant change in the His-Purkinje system conduction time (HV). 1.5. A significant increase in the global ERP, primarily involving the atrial contractile tissue ERP, and further the atrioventricular node ERP.

Animals↗
PubMedDate not supplied

[Pharmacologic complications of the unequal reactivity of constituent elements of the myocardium to the parasympathetic system].

Pharmacological consequences of the unequal reactivity of the myocardial different parts to parasympathic system. The effects of acetylcholine on the various levels of cardiac automatism are studied on open chest dogs with extracorporeal circulation. This drug depresses the sinus node, and more specially the atrio-ventricular node (AV node), but does not alter the His bundle and the Purkinje fibers activity. The sensitivity of the intra-cardiac conduction to acetylcholine also depends upon the considered level of conduction: measured with a bipolar electrode situated upon the His bundle, this one is lowered electively in the atrio-ventricular part. So, the A, V. node can be considered as the elective place of action of acetylcholine on the double point of view of automatism and conduction. Drugs modifying the vagal tonus see their action altered, either in a plus way (antiarrhythmic agents), either in a minus way (cardiac glycosides, halogenated hydrocarbons).

Acetylcholine↗
PubMedDate not supplied

[Evaluation of the potential cardiotoxicity of propranolol-lithium gluconate association (author's transl)].

The association B blocking agent-lithium salt is used for the therapy of some severe hyperthyroidism with cardiotoxicosis. Separately, both drugs depress intracardiac conduction. However by recording the potentials of the His bundle in anesthetized dogs, a potential cardiotoxicity of this association is unlikely since sinusal automaticity alone is importantly slowed. But, these results need further confirmation in man.

Animals↗
PubMedDate not supplied

[French pharmacovigilance database system: examples of utilisation].

UNLABELLED: The French drug surveillance (pharmacovigilance) system is based on a network of 31 regional centres which receive adverse drug reaction (ADR) reports from health professionals and are drug information centers. Cases are entered into a common database, with causality scores. This database contains large amounts of data, which may be used for pharmaco-epidemiological studies. As an example, all cases in which an antihypertensive drug, suspect or not, was cited were identified. ACE-inhibitor cough was also explored. RESULTS: Since 1985, > 70,000 case reports have been entered into the database. 63 per cent were reported by specialists, 20 per cent by GPs. 54 per cent came from University Hospitals, 21 per cent from private practice. The most numerous age group was 60 to 69. The overall sex ratio (F/M) was 1.28, the female preponderance being most marked at < 39 and > 70 years of age. 43 per cent took only one drug, 20 per cent two drugs, 13.4 per cent three, and 24 per cent > three drugs. The most frequently reported effects concerned the skin and appendages (15 per cent), general status and central nervous system (9.5 per cent each), platelets, liver, and GI systems (6 per cent each). Outcome was favourable in 74 per cent. Dechallenge was positive in 71 per cent, rechallence in 6 per cent. 3.4 per cent of the patients died; in 2.2 per cent death was related to a reaction. Causality assessment indicated close temporal relationship (C2 or C3) in 69 per cent of cases; in 51 per cent of cases, no other obvious cause was found. 66 per cent of the reactions were labelled when reported. The database could also be used to explore drug utilisation: as an example, we studied the age and sex distribution of reports containing antihypertensive drugs, irrespective of their possible causal role in the reaction. Antihypertensives were mentioned in 14 per cent of the reports. The age distribution was skewed towards greater age, with a maximum of 70 years. F/M was 1.57, with more M use < 20 and 30-59, whereas F were more common between 20-29 and 60 years. beta-blockers were more often associated with patients under 70, whereas above 70 diuretics and centrally acting antihypertensive drugs were more often reported. This could be related to greater use or worse tolerance of these drugs. As an example of the exploration of a specific drug-reaction relationship, we explored the relationship between the use of ACE inhibitors (ACEI) and cough. ACE inhibitors were present in 6 per cent of cases, but in 75 per cent of reports of cough. F/M was 1.29 (NS) for all reports concerning ACEI, 1.28 for cough unrelated to ACEI, 2.1 for cough with ACEI (P < 0.05). Cough was present in 12 per cent of all reports concerning ACEI. There was no clear difference between ACEI for cough or sex ratio; women cough more with ACEI. This does not seem related to greater ACEI use by women or to greater sensitivity of women to cough. The reason for this sex difference remains to be explained. There are large amounts of essentially underutilized data in drug surveillance databases. How they can or should be used remains to be validated.

Adult↗
PubMedDate not supplied

[Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].

This paper introduces some comments on the complete text of Good Pharmacovigilance Publishing Practices, which forms appendix number 2 of the Good Pharmacovigilance Practices now published by the French Drug Agency, as was Good Clinical Practices. Each good practice is printed in italic and presented in a frame; the following comments are designed to facilitate its application. The technical terms that are used in this text are presented according to the glossary in Good Pharmacovigilance Practices.

Adverse Drug Reaction Reporting Systems↗